Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain

Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials;  Pain / Anesthetics
Article Date: 11 May 2009 - 5:00 PDT

email to a friend   printer friendly   opinions  

Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.

Breakthrough cancer pain affects up to 95% of all cancer patients and is characterised by sudden, unpredictable episodes of intense pain that occur despite background pain medication. This pain is rapid in onset, often reaching maximum intensity in 5 minutes with a duration of 30-60 minutes.

NasalFent met the primary efficacy endpoint in the phase III study 044. Patients treated with NasalFent showed a statistically significant improvement in Pain Intensity Difference within 15 minutes (PID15) compared to immediate release morphine sulphate (p < 0.04), meaning a greater reduction in pain.

NasalFent is the only one of the new generation of fentanyl products to have demonstrated statistically significant improvements over immediate release morphine sulphate. Significantly better improvements in pain scores for NasalFent versus immediate release morphine sulphate were seen at all subsequent time points indicating that superiority of NasalFent was maintained for 60 minutes after dosing.

NasalFent showed both consistent effectiveness and high acceptability; 94% of patients completed the double-blind part of the study and 70% of patients elected to continue therapy with NasalFent in the long term Phase III safety study.

Professor Marie Fallon, St Columba's Hospice Chair of Palliative Medicine, University of Edinburgh, Edinburgh Cancer Research Centre (CRUK) Western General Hospital Edinburgh, UK stated: "These data are hugely exciting. This is the first time a simple-to-use fentanyl product has been shown to be superior to the standard treatment for breakthrough cancer pain. NasalFent offers the prospect of greatly improving the management of this distressing and common complication of cancer."

Study 044 was conducted in all major western European countries and in India, involving 35 expert investigational sites. A total of 135 patients were screened and 110 (82%) entered the open dose titration phase. 84 (76%) patients participated in the double-blind, double dummy portion of the study. It is planned that data from study 044 will be presented at scientific meetings later in 2009.

Richard de Souza, CEO of Archimedes, commented, "We are delighted with these results from another innovative study of NasalFent in what is the largest and most comprehensive clinical programme for any breakthrough cancer pain product. These data clearly show that NasalFent is superior to the benchmark product for this condition and fully supports the results from study 043 which demonstrate that NasalFent offers pain relief within 5 minutes of dosing and is highly acceptable to patients. Data from our third phase III study, 045, a long-term safety study, including over 500 patients, will be available shortly."

Phase III data on NasalFent confirming best-in-class profile to be presented at major scientific congresses

Data from the phase III study 043 on NasalFent are to be presented at the American Pain Society (APS) on 7 and 8 May by Professor Allen Burton, Professor and Chair at the University of Texas and MD Anderson Cancer Centre in Houston, Texas, and at the European Association of Palliative Care (EAPC) on 9 and 10 May by Dr Russell Portenoy, Chairman, Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York and Dr Donald Taylor, Medical Director and Anesthesiologist, Georgia Center for Cancer Pain Management & Palliative Medicine, Georgia.

Results covering both primary and secondary outcomes show statistical superiority for NasalFent over placebo and provide robust evidence for NasalFent as the first product to have demonstrated both rapid onset of pain relief within five minutes of dosing, and early clinically meaningful pain relief within 10 minutes of dosing. Use of rescue medication was low confirming that NasalFent was also consistently effective. Additional data presented showed that NasalFent produced highly significant improvements across a range of pain assessments. Nasal tolerability was excellent and side effects were generally mild to moderate in intensity and importantly were typical of fentanyl use in this patient population.

Professor Allen Burton, Professor and Chair at the University of Texas and MD Anderson Cancer Centre in Houston, Texas, who participated in the study and is presenting the data at the APS, said: "Breakthrough cancer pain is a significant clinical issue and these data illustrate the potential for NasalFent to offer ultra-rapid, consistent pain relief to the many patients who suffer from this unpredictable and extremely debilitating pain."

American Pain Society 043 abstracts

1. Wallace M, Taylor D, Rauck R, et al. Fentanyl pectin nasal spray (FPNS) with PecSys(R): efficacy, tolerability, and onset of action in the treatment of breakthrough cancer pain (BTCP). Poster #245 presented at: the American Pain Society 28th annual scientific meeting; May 7-9, 2009; San Diego, CA. http://www.ampainsoc.org/db2/abstract/view?poster_id=4141#245. Accessed 6 May 2009.

Access the full poster here.

2. Burton A, Wallace M, Weinstein S, et al. Fentanyl pectin nasal spray (FPNS) with PecSys(R): onset of action, consistency, and acceptability in breakthrough cancer pain (BTCP). Poster #244 presented at: the American Pain Society 28th annual scientific meeting; May 7-9, 2009; San Diego, CA. http://www.ampainsoc.org/db2/abstract/view?poster_id=4140#244. Accessed 6 May 2009.

Source
Archimedes Pharma Limited

• Additional
• References
• Citations